Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
PharmaSurgics AB |
---|---|
Information provided by: | PharmaSurgics AB |
ClinicalTrials.gov Identifier: | NCT00860080 |
The main purpose of this study is to determine whether three different single doses of PXL01 are safe and well tolerated by healthy volunteers. The pharmacokinetic properties of PXL01 (same doses) will also be investigated.
Condition | Intervention | Phase |
---|---|---|
Post-Surgery Adhesion Formation |
Drug: PXL01 Drug: Placebo |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Subject), Parallel Assignment, Safety Study |
Official Title: | A First in Man, Phase I, Single-Blind, Placebo-Controlled Study Investigating the Local Tolerability, Safety and Pharmacokinetics in Three Doses of PXL01 and Placebo in 15 Healthy Volunteers |
Estimated Enrollment: | 15 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
PXL01: Experimental
Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
|
Drug: PXL01
PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
|
Placebo: Placebo Comparator
One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
|
Drug: Placebo
Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
|
The primary objective is to investigate the local tolerability and safety of PXL01 in the doses 10, 20, 40 mg, and placebo. The secondary objective is to investigate the pharmacokinetic properties of PXL01 in single doses of 10, 20, and 40 mg.
This is a single-blind, placebo-controlled, single dose administration study in male healthy volunteers. Each Subject will visit the centre three times; one screening visit, one dose administration visit and one follow-up visit over a period of approximately 3 weeks.
At Visit 1 (screening visit), the Subject will be given verbal and written patient information and the informed consent will be signed. Thereafter, the Subject will be assessed for eligibility. Demography, concomitant medication, and medical history will be documented. A physical examination will be performed and blood/urine will be collected for safety analysis. Tests for HIV, Hepatitis B and C, drug screening and alcohol breath test will be performed. Vital signs and a 12-lead ECG will be recorded.
At Visit 2 (dose administration visit), which will occur 7±3 days after the screening visit, the Subjects will first perform an alcohol breath test and PXL01/placebo will then be administered as an abdominal subcutaneous injection. Blood samples for pharmacokinetic analysis will be drawn, pulse and blood pressure will be recorded, and local tolerability assessments will be performed prior to and 15min, 30min, 45min, 60min, 1h 15min, 1h 30min, 2h, 4h, 8h and 24h after the injection. A 12-lead ECG and body temperature will be recorded prior to dose, 1h, 2h, 4h, 8h and 24h after the injection. Blood will be collected prior to and 24 hours after the injection. Adverse Events (AEs) will be recorded and telemetry heart rythm will be monitored continuously. The Subjects will stay at the clinic for about 26 hours after the injection.
Visit 3 (Follow-up visit) will be performed 5-8 days after Visit 2. A physical examination and local tolerability assessments will be performed. Vital signs, a 12-lead ECG and AEs will be recorded. Blood/urine will be collected for safety analysis.
Each group will start by dosing two Subjects. One Subject will receive placebo and the other active treatment. If there are no safety/tolerability concerns within 48 hours, another three Subjects will receive the dose.
Prior to dose escalation, a safety monitoring board will discuss all safety data. In case of any safety/tolerability concerns, dosing may be discontinued.
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | PharmaSurgics AB ( Margit Mahlapuu/CSO ) |
Study ID Numbers: | PHSU01, EudraCT number: 2008-007506-11 |
Study First Received: | March 10, 2009 |
Last Updated: | April 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00860080 History of Changes |
Health Authority: | Sweden: Medical Products Agency |
post-surgery adhesion formation |
Hyaluronic Acid Adhesions Healthy |
Pathologic Processes Adhesions |